Revance Therapeutics, Inc. (30)
Browse by Contract Category
Contracts
-
Office Lease Agreement dated November 19, 2020
(Filed With SEC on November 20, 2020)
-
First Amendment to Exclusive Distribution Agreement
(Filed With SEC on November 9, 2020)
-
Revance Therapeutics, Inc. Amended and Restated 2014 Inducement Plan
(Filed With SEC on November 9, 2020)
-
Executive Employment Agreement effective July 23, 2020 by and between Revance Therapeutics, Inc. and Aubrey Rankin
(Filed With SEC on November 9, 2020)
-
Loan Agreement, dated May 18, 2020, by and between Revance Therapeutics, Inc. and Hint, Inc
(Filed With SEC on June 10, 2020)
-
License Agreement, dated December 4, 2018, by and between Revance Therapeutics, Inc. and Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd
(Filed With SEC on February 28, 2019)
-
Fifth Amendment to Lease, dated July 1, 2020, by and between Revance Therapeutics, Inc. and BMR-Pacific Research Center LP
(Filed With SEC on August 6, 2020)
-
Form of Lock-Up Agreement by and between Revance Therapeutics, Inc. and each of the parties named in each agreement therein
(Filed With SEC on June 10, 2020)
-
Form of Voting Agreement by and between Revance Therapeutics, Inc. and each of the parties named in each agreement therein
(Filed With SEC on June 10, 2020)
-
Revance Therapeutics, Inc. 2020 Management Bonus Plan
(Filed With SEC on February 26, 2020)
-
Exclusive Distribution Agreement, dated January 10, 2020, by and between Revance Therapeutics, Inc. and Teoxane SA
(Filed With SEC on February 26, 2020)
-
Executive Employment Agreement dated February 17, 2020 by and between Revance Therapeutics, Inc. and Dwight Moxie
(Filed With SEC on February 26, 2020)
-
Separation Agreement effective January 8, 2020 by and between Revance Therapeutics, Inc. and Caryn G. McDowell
(Filed With SEC on February 26, 2020)
-
Executive Employment Agreement effective December 1, 2019 and between Revance Therapeutics, Inc. and Dustin Sjuts
(Filed With SEC on February 26, 2020)
-
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
(Filed With SEC on February 26, 2020)
-
Description of Registrants Securities
(Filed With SEC on February 26, 2020)
-
Indenture, dated as of February 14, 2020, by and between Revance Therapeutics, Inc. and U.S. Bank National Association, as Trustee
(Filed With SEC on February 14, 2020)
-
Underwriting Agreement, dated December 4, 2019, by and among the Company and the Underwriters
(Filed With SEC on December 4, 2019)
-
Amended and Restated Non-Employee Director Compensation Policy
(Filed With SEC on November 4, 2019)
-
Executive Employment Agreement effective October 13, 2019 by and between Revance Therapeutics, Inc. and Mark J. Foley
(Filed With SEC on November 4, 2019)
-
Revance Therapeutics, Inc. Executive Severance Benefit Plan, Amended and Restated effective October 13, 2019
(Filed With SEC on November 4, 2019)
-
Separation Agreement effective October 11, 2019 by and between Revance Therapeutics, Inc. and L. Daniel Browne
(Filed With SEC on November 4, 2019)
-
Amendment #1 to the Collaboration and License Agreement dated August 22, 2019 between Revance Therapeutics, Inc. and Mylan Ireland Ltd
(Filed With SEC on November 4, 2019)
-
Revance Therapeutics, Inc. Executive Severance Benefit Plan, Amended and Restated Effective February 12, 2019
(Filed With SEC on May 9, 2019)
-
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
(Filed With SEC on May 9, 2019)
-
Revance Therapeutics, Inc. 2019 Management Bonus Plan
(Filed With SEC on February 28, 2019)
-
Employment Agreement dated November 7, 2018 by and between Revance Therapeutics, Inc. and Cyril Allouche
(Filed With SEC on February 28, 2019)
-
Executive Employment Agreement dated November 5, 2018 by and between Revance Therapeutics, Inc. and Tobin Schilke
(Filed With SEC on February 28, 2019)
-
Revance Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy
(Filed With SEC on February 28, 2019)
-
Underwriting Agreement, dated January 16, 2019, by and among the Company and the Underwriters
(Filed With SEC on January 17, 2019)